THEARTICLE BY SIMKOET AL. 1 in this issueof The Annals is important for at least 2 reasons. At its most basic level it introduces the activated clotting time (ACT) test, a relatively unrecognized methodfor monitoring heparintherapy,to practitioners. Perhaps even more significantly it emphasizes the most attractive aspect of the ACT test, measurement at the patient'sbedside.
Severalrecent studies have shownthat time is the clinician's worstenemyin treating thrombotic diseases.P If the therapeutic goal for anticoagulation can be achieved within the first24 hours, markedly betteroutcomes can be expected. Giventhat, the authors' suggestion to studythe comparability of the ACT and the activated partial thromboplastin time (aPTT) whenbothare done at the patient's bedside takeson obvious importance.
Many of us have sat patiently at a computer terminal, waited by thephone, or pacedthe nursing unit awaiting the resultsof coagulation tests. Beckeret al.' have shown that this waiting may postponedosing adjustments by a mean of 3 hours and push the time to achieve therapeutic concentrations close to the 24-hour window of maximal benefit,instead of ensuring thatthepatient is within a therapeutic range almost by the end of the shift. Thus, bedside monitoringis a conceptwith distinct merit.
However, a study comparing aPTT and ACT for bedside monitoring of treatment of pulmonary embolism (PE) and deep venous thrombosis (DVT) may have an unresolvablemethodologic problem. The ACT is an excellent method of monitoring high-dose heparin therapy, as used in cardiopulmonary bypass, for example, because of its extendedrange.The aPTTtherapeutic range in most laboratories only goes up to 150 seconds and, althoughit corre-AnnPharmacother 1995;29:1045-6.
Thomas G Burnakls PharmD. Pharmacy Clinical Coordinator. Department of Pharmacy.BaptistMedical Center. 800Prudential Dr.Jacksonville. FL32207•FAX 7041202-3142 Reprints: Thomas G Burnakis PharmD lates well with the ACT within that range" at higher doses of heparin, the values reported by the laboratory would always be ''>150.'' However, morerelevant to the studyproposed is the fact that the ACT, despite its usefulness for supratherapeutic dosages of heparin, tends to lose its accuracy at lower dosagesof heparin such as are used in treating PE and DVT.
As demonstrated in the studyby Reiner et al.,6 only ACT values of more than 225 secondswere predictive of therapeutic or supratherapeutic aPTT values. ACT values of less than 225 seconds were obtainedin patients with subtherapeutic, therapeutic, and supratherapeutic aPTT values. Therefore, dependenceon the ACT at values of less than 225 seconds might lead to inappropriate adjustments in heparin dosages. Another study that used ACT for monitoring therapy of PE and DVT, in which the therapeutic range was established at 150-190 seconds, reported bleeding complications in 50% of patients whose values surpassed 190seconds.' Thus, investigators in a comparative studymightbe confident that the patientwas anticoagulated therapeutically if the ACTvalues were sufficiently high, but wouldbe unsureof what actionto take if the ACT decreasedbelow a certain value. More importantly, in an effort to ensure higherACT values the patients mightbe put at risk of more bleeding.
All of this then begs the question concerning whether we need a study comparing ACT and aPTT for bedside monitoring of anticoagulation in patients with PE or DVT. The answer to this, I believe, may be no. Instead, perhaps we shouldenhancethe knowledge we already have with a study that extends the informationprovided by Becker et al.' This group showedthat the availability of results, decisions concerningdosage, and the time to therapeutic anticoagulationwere considerablyfaster with bedside monitoring. What is only hinted at near the end of the article is the effectthatthis method of monitoring mighthave on patient outcomes and cost, and this is an area that deserves distinctly moreinvestigation.
Historicaldata for central laboratorymonitoring could be established by a retrospective analysis of patients treated for thromboembolic diseases. At that pointthe studyby Beckeret al.' could be reproduced for new patients admitted with thromboembolic disease. Differences in the cost The AnnalsofPharmacotherapy • 1995 October, Volume 29 • 1045 of monitoring, length of stay, treatment failures, and bleeding complications could (assuming confounding factors were eliminated) be related logically to the expedient determination of aPTf and the changes to therapy that information wouldindicate. Besidethe obvious outcomebenefits-that would accrue to patients, cost savings and cost avoidance couldbe calculated.
Obviously, there are methodologic concerns with such a study that must be addressed. The 2 groups, historical and prospective, must be comparable in terms of age, sex, weight, diagnosis, and concomitant disease. A way to ensure this comparability might be to acquire the prospective groupfirst and then perform a retrospective reviewof previous admissions withattention to matching patients. Also, one cannotassume that the situation in the studyby Becker et al., that is, highly trained cardiac care unit nurses comfortable with performing various monitoring procedures in a contained environment, would be analogous to monitoring performed on many standardnursing units throughout the hospital. Therefore, an extensivetrainingprogramfor personnel who would perform the bedside monitoring would need to be completed and internal checks for the continued accuracy of this monitoring established.
The final pointto address is that of cost-effectiveness. It is unlikely that, in terms of actual costs for performing tests, bedside monitoring will be less expensive than that performed by a central laboratory. Depending on the size of the institution and the numberof aPTf tests performed daily, numerous monitoring units may need to be purchased. Additionally, because of batch processing and economies of scale, the cost of a disposable reagent cartridgeis undoubtedly more than the cost of materials for a singledetermination by the laboratory. Finally, a reduction in laboratory personnel is improbable, as other laboratory tests still would need to be performed, and even if the number of laboratory technicians could be reduced, this mightbe more thanoffsetby an increased numberof higher paid nursing personnel to perform the tests at the bedside. However, the potential to reduceturnaround time for results and more rapidly achieve therapeutic anticoagulation could result in a reduction in the lengthof stay. Similarly, more timely results mightprevent complications such as bleedingsecondary to prolonged supratherapeutic anticoagulation or rethrombosis as a resultof a decrease in the degree of anticoagulation. Preventing eitherof thesecondi-tions might reduce time spent in the hospitaland costs associated with managing the complications. If only 1 day couldbesavedand we use conservative figures of $400/day for a hospital admission and 250 patientstreated per year, $100000 cost avoidance would be accomplished. Indeed, even if the length of stay were not affected, the outcomes of more timely achievement of therapeutic anticoagulation and reducedoccurrenceof bleedingand rethrombosis are worthy objectives in themselves.
Therefore, instead of expending resources for a study to establish a new way to monitoranticoagulation, particularly when this new method may not be accurate enough to monitor the majority of clinical situations in whichit is applied(i.e., PE, DVT) perhaps we shouldstudy ways to improve the statusquo. The aPTf is used to monitorheparin therapy by more than 90% of all laboratories" and is familiar to almost every practicingclinician. However, general acceptance and familiarity does not implyoptimal use, and if institution of new ideas can both reduce the length of stay and improve outcomes, our research efforts will be rewarded morerichly.
